Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
William Lewis	Officer	2026-07-09	11K shares	$1.26M
Martina Flammer	Officer	2026-07-06	12K shares	$1.35M
Lewis William	Officer	2026-06-25	21K shares	$2.21M
Smith Michael Alexander	Officer	2026-06-22	2K shares	$173K
Lewis William	Officer	2026-06-08	7K shares	$613K
Flammer Martina M.D.	Officer	2026-06-05	2K shares	$193K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-16

2026-07-16

Insmed released 12-month safety and efficacy data from an ongoing open-label extension study of its treprostinil palmitil inhalation powder for pulmonary arterial hypertension. The announcement was made via a press release on July 16, 2026, and the company also scheduled a conference call for the same day to discuss the results.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding INSMED INC (INSM)?

Major stakeholders currently include Jpmorgan Chase & Co ($3.7B), BlackRock, Inc. ($2.7B), Darwin Global Management, Ltd. ($2.6B). Based on the latest 13F filings, there are a total of 673 tracked investment funds and institutions maintaining positions in INSM.

What is the overall institutional sentiment toward INSM recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $2.7B, driven by 380 managers accumulating shares while 312 reduced their exposure.

Which institutions have been selling or reducing their INSM positions?

In the latest period, 215 funds trimmed their holdings, and 97 managers completely exited their positions. The aggregate reported sell value was $14.2B.

Are there any notable investors adding INSM to their portfolios?

Yes, buying activity remains notable. 89 institutions opened new positions in {ticker}, and 291 existing holders added to their shares. The total reported buy value for the quarter amounted to $23.0B.